<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396069</url>
  </required_header>
  <id_info>
    <org_study_id>JP-NC-P1-14</org_study_id>
    <nct_id>NCT02396069</nct_id>
  </id_info>
  <brief_title>The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, placebo control, multiple dose, dose escalation study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I clinical study, randomized, double-blind, placebo-controlled, multiple doses, dose
      escalation study of the safety, tolerability and pharmacokinetics/pharmacodynamics of JPI-289
      in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss and Cmax,ss(76h), Relative PAR level(73h,%)</measure>
    <time_frame>96 hours, 73 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cav,ss</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd,ss</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>JPI-289</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JPI-289</intervention_name>
    <description>PARP-1 inhibitor</description>
    <arm_group_label>JPI-289</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~55 years healthy male

          -  BMI measurement 20kg/m²~27kg/m²

          -  90 ≤ SBP＜140(mmHg) 60 ≤ DBP＜100(mmHg) 45 ≤ Pulse rate＜100(bpm)

          -  Signed the informed consent form to participate voluntarily and to comply with the
             trial requirements

          -  For a follow-up visit and during the study period, blood samples and availability

        Exclusion Criteria:

          -  History of clinically significant hepatic, gastrointestinal, pulmonary,
             musculoskeletal, endocrine, psychiatric, hematooncologic, cardiovascular (Specially
             asthma, obstructive pulmonary disease, peptic ulcer)

          -  History of skin disease of graft affecting absorption of the drug

          -  History of drug abuse

          -  Positive urine drug screening

          -  Administrated investigational product in a previous clinical trial within 60 days of
             the screening test

          -  Donated blood within 60 days prior to screening test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Seok Lim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

